Novavax, Inc. (NASDAQ:NVAX) Shares Sold by Barclays PLC

Barclays PLC trimmed its position in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 41.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 413,467 shares of the biopharmaceutical company's stock after selling 296,112 shares during the period. Barclays PLC owned 0.26% of Novavax worth $3,325,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. E Fund Management Co. Ltd. boosted its stake in Novavax by 5.1% during the 4th quarter. E Fund Management Co. Ltd. now owns 25,340 shares of the biopharmaceutical company's stock valued at $204,000 after purchasing an additional 1,219 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Novavax by 0.4% in the fourth quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company's stock valued at $3,509,000 after acquiring an additional 1,664 shares in the last quarter. Federated Hermes Inc. increased its stake in shares of Novavax by 4.4% during the fourth quarter. Federated Hermes Inc. now owns 50,506 shares of the biopharmaceutical company's stock valued at $406,000 after acquiring an additional 2,124 shares during the period. Summit Investment Advisors Inc. raised its holdings in Novavax by 16.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 16,126 shares of the biopharmaceutical company's stock worth $130,000 after purchasing an additional 2,287 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in Novavax by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,965 shares of the biopharmaceutical company's stock worth $273,000 after purchasing an additional 3,174 shares during the period. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax Stock Up 0.4 %

Shares of NASDAQ NVAX opened at $6.70 on Tuesday. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -2.96, a PEG ratio of 2.85 and a beta of 3.15. The stock's fifty day simple moving average is $7.10 and its 200 day simple moving average is $8.28. Novavax, Inc. has a 52-week low of $4.10 and a 52-week high of $23.86.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million during the quarter, compared to analyst estimates of $85.48 million. During the same quarter in the previous year, the firm earned ($1.44) earnings per share. As a group, analysts anticipate that Novavax, Inc. will post -1.46 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on NVAX shares. TD Cowen upgraded Novavax to a "hold" rating in a research report on Thursday, February 27th. BTIG Research started coverage on Novavax in a research report on Friday, February 28th. They set a "buy" rating and a $19.00 price target on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Novavax presently has an average rating of "Hold" and a consensus price target of $18.00.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.